%0 Journal Article
%T Indeterminate Findings on Oncologic PET/CT: What Difference Does PET/MRI Make?
%A Farrokh Dehdashti
%A Jonathan McConathy
%A Kathryn J. Fowler
%A Tyler J. Fraum
%J Archive of "Nuclear Medicine and Molecular Imaging".
%D 2016
%R 10.1007/s13139-016-0405-1
%X Positron emission tomography/computed tomography (PET/CT) with 2-deoxy-2-[18F]fluoro-D-glucose (FDG) has become the standard of care for the initial staging and subsequent treatment response assessment of many different malignancies. Despite this success, PET/CT is often supplemented by MRI to improve assessment of local tumor invasion and to facilitate detection of lesions in organs with high background FDG uptake. Consequently, PET/MRI has the potential to expand the clinical value of PET examinations by increasing reader certainty and reducing the need for subsequent imaging. This study evaluates the ability of FDG-PET/MRI to clarify findings initially deemed indeterminate on clinical FDG-PET/CT studies
%K Clinical oncology
%K Magnetic resonance imaging
%K Multimodal imaging
%K Positron emission tomography
%K Whole-body imaging
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5135691/